Topical lipophilic epigallocatechin-3-gallate on herpes labialis: A phase II clinical trial of AverTeaX formula

Man Zhao, Rong Zheng, Jinyan Jiang, Douglas Dickinson, Baiping Fu, Tin Chun Chu, Lee Hwang Lee, Henna Pearl, Stephen Hsu

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Objective Previous in vitro and in vivo studies indicated that catechins from the tea plant (Camellia sinensis) have a therapeutic effect on herpes simplex virus infections. The aim of this study was to clinically evaluate a topical proprietary formulation containing lipophilic catechins (AverTeaX, Camellix, LLC, Evans, GA, USA) on recurrent herpes labialis. Study Design A double-blind, placebo-controlled, randomized trial with 40 participants, initially in two groups. Results Compared with the vehicle (100% glycerin USP, CVS Pharmacies, Inc., Woonsocket, RI, USA) group, AverTeaX applied topically six to eight times daily resulted in a significant reduction in clinical episode duration (median 4.5 days vs. 9 days; P =.003) and shortened blistering and ulceration stages within an episode from a median of 3 days to 1 day (P =.0003). Median quality-of-life scores, based on a multiquestion survey, showed significant differences between the groups with respect to duration of itching, from a median of 4 days to 1 day (P =.0021), and duration until symptom free, from a median of 8 days to 4 days (P =.0016). Significant differences were not found for median scores for itching, pain, burning, swelling, bleeding, and stress. Adverse effects were not reported. Conclusion AverTeaX formulation containing lipophilic catechins effectively inhibited herpes simplex labialis infection with clinical significance.

Original languageEnglish
Pages (from-to)717-724
Number of pages8
JournalOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Volume120
Issue number6
DOIs
StatePublished - 1 Dec 2015

Fingerprint Dive into the research topics of 'Topical lipophilic epigallocatechin-3-gallate on herpes labialis: A phase II clinical trial of AverTeaX formula'. Together they form a unique fingerprint.

  • Cite this